ArticleNew microbes and new infections2025
Trends and relationship between antibiotic consumption and carbapenem-resistant Gram-negative bacteria at a tertiary hospital in shaanxi, China from 2011 to 2023.
Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Development of a predictive model using automated machine learning for Carbapenem-resistant Organisms (CRO) infections in hospitalized patients.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant infections are increasing, posing a serious public health threat. This study investigates the relationship between carbapenem-resistant Gram-negative (CRGN) organisms and antimicrobial consumption in a tertiary hospital from 2011 to 2023, particularly focusing on carbapenem consumption. Methods: A retrospective analysis was conducted on quarterly data from 2011 to 2023 at the First Affiliated Hospital of Xi'an Jiaotong University (FAHXJU), covering antibiotic consumption and the incidence rates of carbapenem-resistant Results: First, the total antibiotics consumption remained stable (β = 0.039, Conclusion: Despite stable overall antibiotic use, carbapenem consumption has increased substantially and is significantly correlated with the rising resistance of CRKP and CREC. Targeted antimicrobial stewardship and empirical therapy optimization are urgently needed, with future multicenter studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.